PharmaCyte BiotechPMCB -0.30%32 Interest Coverage is No Debt (1) as of Jan. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 377 Biotechnology companies, PharmaCyte Biotech ranks better than 99.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. PharmaCyte Biotech's
Operating Income
for the
three
months ended in Jan. 2026 was $-2.12 Mil. PharmaCyte Biotech's Interest Expense for the
three
months ended in Jan. 2026 was $0.00 Mil.
PharmaCyte Biotech has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
PharmaCyte Biotech Inc has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for PharmaCyte Biotech's Interest Coverage or its related term are showing as below:
PMCB'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
PMCB's Interest Coverage is ranked better than 99.2% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs PMCB: No Debt
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
PharmaCyte Biotech Interest Coverage Related Terms
PharmaCyte Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PMCB vs IMNN, ACXP, ENVB: Interest Coverage Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
PharmaCyte Biotech (PMCB) has a Interest Coverage of No Debt (1) as of Jan. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaCyte Biotech and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, PharmaCyte Biotech's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, PharmaCyte Biotech ranks #3 out of 377 companies in the Biotechnology industry, placing it in the top 0.8%.
Is PharmaCyte Biotech's Interest Coverage too high?
PharmaCyte Biotech's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, PharmaCyte Biotech ranks #3 out of 377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Interest Coverage compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #3 out of 377 companies for Interest Coverage. This places PharmaCyte Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 106.07. Historically, PharmaCyte Biotech's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Interest Coverage is No Debt (1) as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
